MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development

Holger Heyn1, Maria Engelmann, Sabine Schreek

  • 1Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.

Insights

MicroRNA-335 (miR-335) acts as a tumor suppressor in breast cancer by regulating the BRCA1 network. Decreased miR-335 levels correlate with breast cancer, impacting cell viability and apoptosis.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) are key regulators in cancer, acting as oncogenes or tumor suppressors.
  • The role of specific miRNAs, like miR-335, in sporadic human breast cancer and their interaction with the BRCA1 network requires further investigation.

Purpose of the Study:

  • To investigate the role of miR-335 in sporadic human breast cancer formation.
  • To elucidate miR-335's involvement in the regulatory network of the breast cancer susceptibility gene BRCA1.
  • To assess the functional impact of miR-335 on breast cancer cells.

Main Methods:

  • MicroRNA overexpression in cell culture models.
  • Protein analysis and luciferase reporter assays.
  • Analysis of primary sporadic breast cancer specimens.

Main Results:

  • miR-335 was identified as a regulator of BRCA1 activators (ERα, IGF1R, SP1) and repressor (ID4), with feedback regulation by estrogens.
  • Overexpression of miR-335 led to increased BRCA1 mRNA expression, suggesting ID4 signaling dominance.
  • Significantly decreased miR-335 levels were observed in sporadic breast cancer tissues compared to normal controls, correlating positively with BRCA1 transcript levels.
  • miR-335 overexpression decreased cell viability and increased apoptosis, confirming its tumor-suppressive function.

Conclusions:

  • miR-335 plays a crucial role in the BRCA1 regulatory cascade, impacting cell proliferation and apoptosis.
  • Deregulation of miR-335 during breast cancer development may contribute to tumorigenesis by inactivating tumor-suppressive signals.
  • miR-335 functions as a tumor suppressor in breast cancer, making it a potential therapeutic target.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...